Transgenomic, Inc. (TBIO) Announces Global Availability of CRC RAScan Mutation Detection Test for Use in Patients With Metastatic Colorectal Cancer to Help Identify Appropriate Treatment
5/16/2013 11:30:38 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO) today announced the global, commercial availability of CRC RAScan™, a new mutation detection test to screen patients with metastatic colorectal cancer (mCRC) for RAS mutations (KRAS and NRAS). These RAS mutations, identified using the CRC RAScan™ kits which use Surveyor®-Wave® technology, provide physicians with important information regarding tumor mutation status to help with clinical treatment decisions for their mCRC patients. Transgenomic’s CLIA-certified laboratory in the United States (U.S.) is available immediately to receive patient samples for testing. In Europe, CE-IVD registered test kits are available for purchase. Research-only test kits will soon be available for purchase in the U.S.
Help employers find you! Check out all the jobs and post your resume.
comments powered by